BR112017006447A2 - processo de conjugação e conjugados sintéticos de oligossacarídeo-proteína obtidos dos mesmos - Google Patents

processo de conjugação e conjugados sintéticos de oligossacarídeo-proteína obtidos dos mesmos

Info

Publication number
BR112017006447A2
BR112017006447A2 BR112017006447A BR112017006447A BR112017006447A2 BR 112017006447 A2 BR112017006447 A2 BR 112017006447A2 BR 112017006447 A BR112017006447 A BR 112017006447A BR 112017006447 A BR112017006447 A BR 112017006447A BR 112017006447 A2 BR112017006447 A2 BR 112017006447A2
Authority
BR
Brazil
Prior art keywords
oligosaccharide
synthetic
protein
conjugates
present
Prior art date
Application number
BR112017006447A
Other languages
English (en)
Inventor
Gill Davinder
Singh Deepti
Dalal Juned
Kumar Chhikara Manoj
Rana Rakesh
Original Assignee
Msd Wellcome Trust Hilleman Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Wellcome Trust Hilleman Laboratories Pvt Ltd filed Critical Msd Wellcome Trust Hilleman Laboratories Pvt Ltd
Publication of BR112017006447A2 publication Critical patent/BR112017006447A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção se refere a um processo melhorado de conjugação para obter conjugados sintéticos de oligossacarídeo ? proteína (os-pr). o processo de conjugação de os-pr sintético é um processo rápido fornecendo conjugados de oligossacarídeo ? proteína que são altamente imunogênicos e evocam respostas imunes específicas e homogêneas. o oligossacarídeo sintético compreendendo de quatro a oito unidades de repetição dos respectivos monômeros e pelo menos um ligador de terminal amino embutido, o dito polissacarídeo sintético imita o polissacarídeo natural obtido de bactérias gram negativas tais como os sorogrupos a, c, y, w, x de neisseria meningitidis e haemophilus influenzae e a proteína carregadora é obtida de bactérias gram positivas tais como clostridium tetani (toxóide do tétano) ou corynebacterium diphtheriae (crm197) ou suas versões recombinantes. a química da conjugação do dito conjugado de oligossacarídeo-proteína da presente invenção é a da ligação de tio-éter. a presente invenção consome um tempo de processo completo na faixa de 14 a 22 horas. os ditos conjugados de oligossacarídeo-proteína são úteis na produção de vacina monovalente ou vacinas de combinação multivalentes e como ferramenta de diagnóstico.
BR112017006447A 2014-10-09 2015-10-08 processo de conjugação e conjugados sintéticos de oligossacarídeo-proteína obtidos dos mesmos BR112017006447A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2884DE2014 2014-10-09
PCT/IB2015/057682 WO2016055957A1 (en) 2014-10-09 2015-10-08 An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof

Publications (1)

Publication Number Publication Date
BR112017006447A2 true BR112017006447A2 (pt) 2017-12-12

Family

ID=55652678

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006447A BR112017006447A2 (pt) 2014-10-09 2015-10-08 processo de conjugação e conjugados sintéticos de oligossacarídeo-proteína obtidos dos mesmos

Country Status (18)

Country Link
US (1) US10105438B2 (pt)
EP (1) EP3204396A4 (pt)
JP (1) JP2017531662A (pt)
KR (1) KR20170065030A (pt)
CN (1) CN106795194A (pt)
AU (1) AU2015329590B2 (pt)
BR (1) BR112017006447A2 (pt)
CA (1) CA2963900A1 (pt)
CL (1) CL2017000844A1 (pt)
CO (1) CO2017003291A2 (pt)
CU (1) CU20170046A7 (pt)
EA (1) EA201700177A1 (pt)
IL (1) IL251511A0 (pt)
MX (1) MX2017004495A (pt)
PH (1) PH12017500579A1 (pt)
SG (1) SG11201702451WA (pt)
TN (1) TN2017000126A1 (pt)
WO (1) WO2016055957A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170198004A1 (en) 2014-05-24 2017-07-13 Biological E Limited Novel semi-synthetic meningococcal conjugate vaccine
BR112018001425A2 (pt) * 2015-07-28 2018-09-11 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd novos oligômeros de sorogrupo y de neisseria meningitidis e processos de sintetização dos mesmos
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
BR112019026192B1 (pt) 2017-06-10 2022-05-10 Inventprise, Llc Vacinas de conjugado multivalente com polissacarídeos de conjugado bivalente ou multivalente que fornecem imunogenicidade e avidez melhoradas
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP7297047B2 (ja) * 2018-03-23 2023-06-23 コラネックス・キャピタル 治療用ツールとしての精密なグリココンジュゲート
CN113274488B (zh) * 2021-04-30 2023-08-29 山东省药学科学院 一种特异性预防真菌感染的寡糖疫苗及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434668A1 (en) * 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
RU2412944C2 (ru) * 2005-05-06 2011-02-27 Новартис Вэксинз Энд Дайагностикс Срл Иммуногены для вакцин против менингита а
FR2904627B1 (fr) * 2006-08-04 2008-11-07 Pasteur Institut Nouveaux peptides actives, purifies et isoles, derives du recepteur cd4 (mini-cd4) et leur procece de preparation
CA2819366A1 (en) * 2010-12-10 2012-06-14 Merck Sharp & Dohme Corp. Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process

Also Published As

Publication number Publication date
AU2015329590A1 (en) 2017-05-04
EP3204396A4 (en) 2018-03-28
TN2017000126A1 (en) 2018-10-19
US20170246313A1 (en) 2017-08-31
KR20170065030A (ko) 2017-06-12
CL2017000844A1 (es) 2017-12-22
AU2015329590B2 (en) 2019-08-22
CO2017003291A2 (es) 2017-06-30
IL251511A0 (en) 2017-05-29
PH12017500579A1 (en) 2017-08-30
EP3204396A1 (en) 2017-08-16
US10105438B2 (en) 2018-10-23
SG11201702451WA (en) 2017-04-27
EA201700177A1 (ru) 2017-07-31
CU20170046A7 (es) 2017-06-05
JP2017531662A (ja) 2017-10-26
CA2963900A1 (en) 2016-04-14
WO2016055957A1 (en) 2016-04-14
MX2017004495A (es) 2017-12-18
CN106795194A (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
BR112017006447A2 (pt) processo de conjugação e conjugados sintéticos de oligossacarídeo-proteína obtidos dos mesmos
BR112020004471A8 (pt) Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
BR112020004410A8 (pt) Processos para a formulação de polissacarídeos pneumocócicos para conjugação a uma proteína carreadora
BR112020004396A8 (pt) Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
BR112020004502A8 (pt) Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
CY1120512T1 (el) Βιοσυζευγματα κατασκευασμενα απο ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα
BR112019001995A2 (pt) composição de conjugado de polissacarídeo pneumocócico multivalente ? proteína
PE20220774A1 (es) Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
BR112018007812A2 (pt) polissacarídeo capsular, processo para preparar um polissacarídeo capsular e para fabricar uma vacina, composição imunogênica, vacina, métodos para tratamento ou prevenção de uma infecção, para imunizar um hospedeiro humano e para induzir uma resposta imune, e, uso de uma composição imunogênica.
MX2013013111A (es) Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma.
MX2020002555A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
CO7240387A2 (es) Composición conjugada de polisacáridos-proteínas neumocócica polivalente
AR092897A1 (es) Composiciones inmunogenicas
CY1118801T1 (el) Πεπτιδια, προϊοντα συζευξης και μεθοδος για την αυξηση της ανοσογονικοτητας ενος εμβολιου
BR112015008419A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina
MX354103B (es) Composicion inmunogenica.
PH12016500360A1 (en) A bacterial vaccine and methods for manufacture thereof
MX2018010920A (es) Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos.
BRPI0516770A (pt) vacina e conjugados de proteìna - derivados de polissacarìdeo de meningocócico multivalente
CO2021007863A2 (es) Vacuna conjugada polisacárido-proteína neumocócica multivalente
CY1123600T1 (el) Μεθοδος θεραπειας
BR112018017174A2 (pt) conjugados de aminoácido e peptídeo e processo de conjugação
MY194920A (en) Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof
BR112019003419A2 (pt) composição de vacina multivalente
BRPI0516372A (pt) conjugados de polissacarìdeo-proteìna derivatizados meningocócicos multivalentes e vacina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]